By Denny Jacob
Foghorn Therapeutics Inc. shares sank 26% to $8.48 in late trading Thursday after the company said the Food and Drug Administration placed its Phase 1 study of FHD-286 on a partial clinical hold.
The development stage biopharmaceutical company said the partial clinical hold came after a recent death that occurred in a subject with potential differentiation syndrome. Until the partial clinical hold for the study has been resolved, the company said it is suspending guidance on the timing of the data release for the dose escalation phase of the FHD-286 program.
The Phase 1 dose escalation study of FHD-286 is for relapsed and/or refractory acute myelogenous leukemia and myelodysplastic syndrome, Foghorn Therapeutics said. The FDA has requested a review of the safety database, risk mitigation strategies and a breakdown of clinical activity across dose levels, the company said.
Write to Denny Jacob at firstname.lastname@example.org
(END) Dow Jones Newswires
May 19, 2022 18:05 ET (22:05 GMT)Copyright (c) 2022 Dow Jones & Company, Inc.